Le Lézard
Classified in: Health
Subjects: CHI, AVO

Trump Administration Must Put Kids Before Juul and Take Mint/Menthol E-Cigarettes Off the Market


WASHINGTON, Oct. 25, 2019 /PRNewswire/ -- As organizations committed to protecting the health of our nation's children, we strongly urge the Trump Administration to side with America's kids over the tobacco industry by implementing its plan to clear the market of all flavored e-cigarettes ? including mint and menthol flavors that are used by nearly two-thirds of high school e-cigarette users.

A failure to remove mint and menthol e-cigarettes from the market would be a capitulation to Juul and other companies that created the worsening youth e-cigarette epidemic. This is exactly what Juul and its part-owner Altria want as Juul made clear last week when it suspended sales of other flavors, but not mint and menthol. Allowing continued mint and menthol sales would prioritize Juul's profits over kids' health as these flavors are very popular with teens and make up the vast majority of Juul's sales (The New York Times and other media have reported that mint and menthol account for about 80% of Juul's sales). We will not solve this public health crisis unless all flavored e-cigarettes are eliminated, including mint and menthol.

There is no public health justification for allowing continued sales of mint and menthol e-cigarettes, as the Administration itself made clear on September 11 when it announced its plan to remove all flavored e-cigarettes, including mint and menthol. According to preliminary data from the 2019 National Youth Tobacco Survey released by the Administration, 63.9% of high school e-cigarette users used mint and menthol flavors in 2019, up from 51.2% in 2018 and 42.3% in 2017. If mint and menthol are left on the market, even more kids will migrate to them. Health and Human Services Secretary Alex Azar was absolutely right when he spoke of a "huge spiking" in youth use of mint and menthol e-cigarettes and stated, "These products are still getting to kids and we cannot let a whole generation get addicted to them through mint and menthol and other flavors."

Federal regulators have repeatedly failed to take the decisive action needed to protect our kids and head off the youth e-cigarette epidemic. With Secretary Azar reporting that 5 million kids now using e-cigarettes, we cannot afford further delay. We urge the Trump Administration to stand up to the tobacco industry and swiftly implement its plan to clear the market of all flavored e-cigarettes, including mint and menthol.

SOURCE Campaign for Tobacco-Free Kids


These press releases may also interest you

at 03:00
Sadly, senior citizens are among the first to suffer from exposure to COVID-19. Living in close quarters is one of the highest contributing factors to exposure but the team from San Luis Obispo's Elder Placement Professionals has prepared some...

4 jui 2020
SummaryProducts: Cetrotide 0.25mg Issue: One lot of Cetrotide 0.25mg is being recalled because some vials may have missing stoppers, which could make the product unsterile. What to do: Check the lot number on your product or contact your pharmacist...

4 jui 2020
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 105,091 cases of COVID-19 in Canada, including 8,663 deaths. 65% of people have now recovered....

4 jui 2020
The latest data of the evolution of COVID-19 in Québec reveal 102 new cases over the past 24 hours, bringing the total number of people infected to 55,784. During the same period, 3 new deaths were recorded, to which are added 3 deaths that occurred...

4 jui 2020
On Friday, the British government announced that, as of July 10th, those travelling from the Commonwealth of Dominica to England need not self-isolate for 14 days. Dominica is one of the 59 countries and 14 British Overseas Territories forming a...

4 jui 2020
Gilead Sciences, Inc. today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company's investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained...



News published on 25 october 2019 at 15:38 and distributed by: